Enhancement of immunostimulatory properties of exosomal vaccines by incorporation of fusion-competent G protein of vesicular stomatitis virus

Vaccine

Volumn 26, Issue 29-30, 2008, Pages 3662-3672

  Temchura, Vladimir V ^a   Tenbusch, Matthias ^a   Nchinda, Godwin ^a   Nabi, Ghulam ^a   Tippler, Bettina ^a   Zelenyuk, Maryna ^a   Wildner, Oliver ^a   Überla, Klaus ^a   Kuate, Seraphin ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Exosomes; Vaccines; VSV G

Indexed keywords

DNA VACCINE; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN G2A ANTIBODY; OVALBUMIN; PLASMID DNA; VIRUS FUSION PROTEIN; VIRUS VACCINE; VIRUS VECTOR;

ACIDIFICATION; ANIMAL CELL; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CANCER GENE THERAPY; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG MECHANISM; ENDOSOME; EXOSOME; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; MELANOMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEIN TRANSPORT; TRANSPORT VESICLE; TUMOR CELL; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION;

ANIMALS; ANTIBODIES; ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; ENDOSOMES; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASMS; OVALBUMIN; PROTEIN TRANSPORT; SECRETORY VESICLES; VACCINES; VIRAL ENVELOPE PROTEINS;

EID: 45049087024     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.04.069     Document Type: Article

References (32)

1. Zitvogel L., Fernandez N., Lozier A., Wolfers J., Regnault A., Raposo G., et al. Dendritic cells or their exosomes are effective biotherapies of cancer. Eur J Cancer 35 Suppl 3 (1999) 36-38
2. Andre F., Schartz N.E., Chaput N., Flament C., Raposo G., Amigorena S., et al. Tumor-derived exosomes: a new source of tumor rejection antigens. Vaccine 20 Suppl 4 (2002) A28-A31
3. Chaput N., Schartz N.E., Andre F., Taieb J., Novault S., Bonnaventure P., et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol 172 (2004) 2137-2146
4. Taieb J., Chaput N., and Zitvogel L. Dendritic cell-derived exosomes as cell-free peptide-based vaccines. Crit Rev Immunol 25 (2005) 215-223
5. Escudier B., Dorval T., Chaput N., André F., Caby M.P., Novault S., et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J Transl Med 3 (2005) 10
6. Mignot G., Roux S., Thery C., Segura E., and Zitvogel L. Prospects for exosomes in immunotherapy of cancer. J Cell Mol Med 10 (2006) 376-388
7. Wubbolts R., Leckie R.S., Veenhuizen P.T., Schwarzmann G., Mobius W., Hoernschemeyer J., et al. Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation. J Biol Chem 278 (2003) 10963-10972
8. Chen W., Wang J., Shao C., Liu S., Yu Y., Wang Q., et al. Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells. Eur J Immunol 36 (2006) 1598-1608
9. Kuate S., Cinatl J., Doerr H.W., and Uberla K. Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies. Virology 362 1 (2007) 26-37
10. Matlin K.S., Reggio H., Helenius A., and Simons K. Pathway of vesicular stomatitis virus entry leading to infection. J Mol Biol 156 (1982) 609-631
11. Buseyne F., Le Gall S., Boccaccio C., Abastado J.P., Lifson J.D., Arthur L.O., et al. MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Nat Med 7 (2001) 344-349
12. Marsac D., Loirat D., Petit C., Schwartz O., and Michel M.L. Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles. J Virol 76 (2002) 7544-7553
13. Kuate S., Stahl-Hennig C., Stoiber H., Nchinda G., Floto A., Franz M., et al. Immunogenicity and efficacy of immunodeficiency virus-like particles pseudotyped with the G protein of vesicular stomatitis virus. Virology 351 (2006) 133-144
14. DuBridge R.B., Tang P., Hsia H.C., Leong P.M., Miller J.H., and Calos M.P. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 7 (1987) 379-387
15. Kuate S., Stefanou D., Hoffmann D., Wildner O., and Uberla K. Production of lentiviral vectors by transient expression of minimal packaging genes from recombinant adenoviruses. J Gene Med 6 (2004) 1197-1205
16. Wagner R., Graf M., Bieler K., Wolf H., Grunwald T., Foley P., et al. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors. Hum Gene Ther 11 (2000) 2403-2413
17. Ternette N., Stefanou D., Kuate S., Uberla K., and Grunwald T. Expression of RNA virus proteins by RNA polymerase II dependent expression plasmids is hindered at multiple steps. Virol J 4 (2007) 51
18. Whitt M.A., Zagouras P., Crise B., and Rose J.K. A fusion-defective mutant of the vesicular stomatitis virus glycoprotein. J Virol 64 (1990) 4907-4913
19. Schulz O., Edwards A.D., Schito M., Aliberti J., Manickasingham S., Sher A., et al. CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity 13 (2000) 453-462
20. Coles R.M., Mueller S.N., Heath W.R., Carbone F.R., and Brooks A.G. Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1. J Immunol 168 (2002) 834-838
21. Chapple S.D., and Jones I.M. Non-polar distribution of green fluorescent protein on the surface of Autographa californica nucleopolyhedrovirus using a heterologous membrane anchor. J Biotechnol 95 (2002) 269-275
22. Kovacsovics-Bankowski M., and Rock K.L. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267 (1995) 243-246
23. Rodriguez A., Regnault A., Kleijmeer M., Ricciardi-Castagnoli P., and Amigorena S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1 (1999) 362-386
24. + T cells in vivo. J Immunol 166 (2001) 4355-4362
25. Rock K.L., Gramm C., Rothstein L., Clark K., Stein R., Dick L., et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78 (1994) 761-771
26. Anton L.C., Snyder H.L., Bennink J.R., Vinitsky A., Orlowski M., Porgador A., et al. Dissociation of proteasomal degradation of biosynthesized viral proteins from generation of MHC class I-associated antigenic peptides. J Immunol 160 (1998) 4859-4868
27. Pichlmair A., Diebold S.S., Gschmeissner S., Takeuchi Y., Ikeda Y., Collins M.K., et al. Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9. J Virol 81 (2007) 539-547
28. Georgel P., Jiang Z., Kunz S., Janssen E., Mols J., Hoebe K., et al. Vesicular stomatitis virus glycoprotein G activates a specific antiviral Toll-like receptor 4-dependent pathway. Virology 362 (2007) 304-313
29. Granelli-Piperno A., Finkel V., Delgado E., and Steinman R.M. Virus replication begins in dendritic cells during the transmission of HIV-1 from mature dendritic cells to T cells. Curr Biol 9 (1999) 21-29
30. Blander J.M., and Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440 (2006) 808-812
31. Blander J.M., and Medzhitov R. Regulation of phagosome maturation by signals from toll-like receptors. Science 304 (2004) 1014-1018
32. Mattes J., Hulett M., Xie W., Hogan S., Rothenberg M.E., Foster P., et al. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med 197 (2003) 387-393